OncXerna Therapeutics
Oncologie Ltd., a China-based precision medicine provider, manufactures innovative biotech products.
Founded
2018Oncologie Ltd., a China-based precision medicine provider, manufactures innovative biotech products.
OncXerna Therapeutics, originally founded as Oncologie Ltd. in China, is a precision medicine provider focused on developing innovative biotechnology products. The company's core mission is to harness the power of RNA-based biomarkers to create targeted cancer therapies, aiming to improve patient outcomes through personalized medicine. OncXerna offers novel pharmaceuticals and drug substances designed to address unmet medical needs in oncology, with a market focus on delivering precision treatments for cancer patients worldwide.
Notable affiliated individuals include industry experts and seasoned professionals in biotechnology and oncology. The company has garnered significant investment from leading venture capital firms specializing in life sciences. Key achievements include the development of proprietary RNA-based biomarker platforms and successful clinical trials demonstrating the efficacy of their targeted therapies. OncXerna's impact lies in its contribution to the advancement of precision oncology, offering hope for more effective and personalized cancer treatments.
Companies similar to OncXerna Therapeutics include OncoPrecision, Xsphera Biosciences, Oncolix and OnCusp Therapeutics.
OncXerna Therapeutics was founded in 2018.
OncXerna Therapeutics' headquarters is located in Waltham, MA, US.
OncXerna Therapeutics' most recent funding round was for $30M (USD) in March 2022.
As of Mar 3, 2022, OncXerna Therapeutics has raised a total of $126.5M (USD).
OncXerna Therapeutics has 11 employees as of Feb 5, 2024.
Oncolix
